CD BioGlyco, a leader in the field of glycobiology, today announced the launch of its anti-glycan antibody development service. The new service provides researchers with a comprehensive solution for developing high-quality, specific, and sensitive anti-glycan antibodies.

Anti-glycan antibodies are necessary for locating glycans, tracking their expression, and identifying the biological effects they have. They can be used to purify glycans and glycoproteins, locate and track the expression of glycans, and assess their relevance to diseases. They can also be used as agonists and antagonists. For instance, many cancers are currently detected and tracked using antibodies that target Sialy Lewis A. Anti-glycan antibodies can significantly advance the fields of glycobiology and glycomedicine from the perspectives of structural diversity, individuality, and disease relevance.

However, there are still issues that need to be resolved, such as figuring out an antibody's specificity and suitability for a given application. To tackle with this, CD BioGlyco developed a series of effective technology platforms, such as continuously optimizing hybridoma or phage display technologies for anti-glycan antibodies, animal models to produce anti-glycan antibodies, and advanced technologies like mass spectrometry and microarray to evaluate antibodies.

Upon the release of this new service, customers now have access to CD BioGlyco’s comprehensive solutions for anti-glycan antibody development.

Anti-glycan Monoclonal Antibody Development

CD BioGlyco improved methods for evaluating antibody specificity and developed a series of first-class technologies such as ELISA, knockout, knockdown, SPR, glycan microarray and mass spectrometry, and combine them to get the best evaluation scheme.

Anti-glycan Polyclonal Antibody Development

CD BioGlyco provides numerous species for the production of anti-glycan polyclonal antibodies, including rabbits, goats, sheep, chickens, mice, rats and hamsters, etc.

Service advantages

· Multiple advanced technology platforms

· Systematic specificity evaluation protocol

· High yield and high specificity

· Production procedures that comply with regulations

· Professional antibody development expert team

“Glycans are essential components of cells and tissues, and they play a critical role in many biological processes,” said Anna, one of the representative speakers at CD BioGlyco. “By offering anti-glycan antibody development services, we are providing researchers with the tools they need to study the role of glycans in health and disease.”

To know more about CD BioGlyco’s anti-glycan antibody development service, please visit https://www.bioglyco.com/anti-glycan-antibody-development.html.